Background {#Sec1}
==========

Urea Cycle Disorders (UCD) are a group of inborn errors of metabolism seen frequently in tertiary care intensive care units (ICUs) in view of the hyperammonemic encephalopathy which is the most common presenting feature. The overall incidence of UCD varies from 1:8000 to 1:44,000 births \[[@CR1]--[@CR4]\]. A more recent study from 3 countries in Europe reported an estimated cumulative incidence of 1 in 51,946 for UCDs \[[@CR5]\]. Incidence of UCD is not known in India. All types of UCDs have been recognized.

The overall outcome of children with UCD remains poor, even in the developed world where excellent infrastructure and facilities are available \[[@CR1], [@CR6]\]. Children with UCD are recognized after symptoms of hyperammonemia such as lethargy and coma occur, thus leading to a significant delay in diagnosis. This may happen in babies who are screened as well, because neonatal hyperammonemic encephalopathy often occur before neonatal screening test results are known. A delay in diagnosis results in either death or neurodisability \[[@CR7], [@CR8]\]. This is exacerbated by a lack of awareness amongst families and primary health care physicians, causing a delay in seeking medical attention. Additional factors in developing countries like India are inadequate facilities in most primary and secondary level hospitals that contribute to a poor outcome. For instance, laboratory ammonia assays are usually only available even in tertiary hospitals. Therefore, a majority of babies die without a diagnosis, or are recognized very late, contributing to increased morbidity and mortality. An accurate genetic diagnosis is essential not only for appropriate management of the child, but also for genetic counseling in the context of subsequent pregnancies and carrier testing. So far, only a few mutations have been reported from India \[[@CR9]--[@CR12]\]. The Indian population is a unique mix of several cultures and sects, with considerable consanguinity. With the distinctness of Indian gene pool, mutations may be different from other populations and perhaps recurrent in some areas in view of closed community marriages, limiting the gene pool to an ethnic group.

We present here our experience in diagnosis, genetic testing and outcome after diagnosis of UCD in these families. The data was collected from two major metabolic centres in India.

Methods {#Sec2}
=======

Patient cohort {#Sec3}
--------------

All neonates and children presenting with hyperammonemia and biochemical/clinical features of UCD since year 2001 till December 2017 were included in the cohort. The patients were collected from two centres. In the first centre at Sir Ganga Ram Hospital, New Delhi, they were chosen either from the genetic clinic or from the molecular genetics laboratory, which received samples for genetic testing for UCD from referring clinicians. A biochemical diagnosis of UCD was taken as the inclusion criteria. In some cases, where DNA of the index patient was not available, parents of the deceased patients were enrolled in the study, where good clinical and biochemical data was available to fulfill the diagnostic criteria. This centre was designated as Centre 1. In addition, cases from another referral centre (Centre 2) in Mumbai (NIRMAN) were also included in this study. All cases with complete clinical, biochemical and molecular genetic data were taken. All parents or legal guardians provided their consent for DNA testing. All the tests were carried out as part of clinical care as diagnostically indicated.

For selection of cases, information of clinical symptoms and hyperammonemia were solicited. This was followed by biochemical analysis of amino acids by Tandem mass spectrometry (MS/MS) on dried blood spots (DBS) or Ultra/ High performance liquid chromatography (U/HPLC) on plasma samples, and quantification of urinary orotic acid by Gas chromatography-mass spectrometry (GC-MS). To confirm the diagnosis of UCD, genetic testing was carried out on DNA extracted from peripheral blood or dried blood spots from affected children or their parents, where the index case's sample was not available. Sequencing of the genes was performed either at Münster University in Germany (2001--2008) or University Children's Hospital in Zurich (2008--2017) or at Sir Ganga Ram Hospital (2008--2017) in New Delhi. Genetic testing was done in cases from both centres. Prenatal diagnosis using chorionic villous sampling (CVS) or amniocentesis and mutation analysis was performed in subsequent pregnancies of families.

Molecular studies for UCD gene mutations {#Sec4}
----------------------------------------

DNA was isolated from human samples using standard methods. PCR products were purified using Multiscreen^R^ PCR~μ96~ plate (MilliPore, USA). Bidirectional sequencing of the coding exons and corresponding intron/exon boundaries were set up using the same primers as for PCR, with purified PCR products using BigDye® Terminator v 3.1 cycle sequencing kit (Applied Biosystems, California). Sequencing was carried out on ABI 3500Dx automated sequencer unit (Applied Biosystems). Sequence chromatograms obtained were analyzed with Chromas software (Technelysium, Tewantin, Australia) and by manual inspection.

Obtained sequences were compared by blasting them against the reference genomic sequences (for *ASS1*: NM_000050, NP000041; for *ASL*: NM_000048, NP_000039; for *OTC*: NM_000531, NP_000522). Bioinformatics analysis was carried out to determine the functional consequences of mutations and their effects on protein structure by using different tools, e.g., Polyphen2 ([genetics.bwh.harvard.edu/pph2/](http://genetics.bwh.harvard.edu/pph2/)), Mutation Taster ([www.mutationtaster.org/](http://www.mutationtaster.org)), or Sorting Intolerant from Tolerant (<http://provean.jcvi.org/index.php>) \[[@CR13]--[@CR15]\].

The probands with suspected OTC deficiency or their mothers (in case of non-availability of DNA from proband due to death prior to diagnosis), were evaluated for deletions/duplications in the *OTC* gene by (Multiplex ligation probe amplification) MLPA probe mix (MRC Holland P079-OTC). Mutation analyses at Münster or Zurich University were done as reported \[[@CR16]--[@CR19]\].

For one patient, cDNA analysis of *CPS1* gene was performed. RNA-isolation and cDNA-synthesis was performed using an established protocol \[[@CR20]\]. Amplification by PCR and direct sequencing of the carbamoylphosphate synthetase 1 transcript was done in 6 overlapping fragments. Ref. sequences: GenBank NM_001875.4 and Ensembl ENSG00000021826, ENST00000233072.

Results {#Sec5}
=======

A total of 148 patients from the two centres were collected, of whom 123 patients from 123 families fulfilled the criteria and were included in the study. Nine patients from Centre 1, and 16 cases from Centre 2 were excluded because of lack of a confirmed diagnosis. Seventy seven cases from Centre 1 and 48 from Centre 2 fulfilled the criteria and were enrolled. In the cohort of patients whose data was collected, 82% have been after year 2007.

The diagnosis was established in all 123 patients; 61 had citrullinemia type 1, 26 patients had OTC deficiency, 20 were of argininosuccinic aciduria (ASA), 9 had arginase deficiency, 3 had carbamoyl phosphate synthetase (CPS1), 2 had N-acetyl glutamate synthase (NAGS) deficiency and one patient each had lysinuric protein intolerance (LPI) and citrin deficiency (Table [1](#Tab1){ref-type="table"}). All patients were diagnosed biochemically by quantitative amino acid analysis on dried blood spots (MS/MS) or in plasma (U/HPLC), except for LPI where both plasma and urine amino acid quantitation was performed by HPLC (see Additional file [1](#MOESM1){ref-type="media"}).Table 1Clinical features and outcomes of the various urea cycle disordersTypes of UCDASS1-DASL-DOTC-DARG-DCPS1-DNAGS-DCitrin-DLPITotalTotal Numbers61202693211123Consanguinity9 (*n* = 54)7 (*n* = 19)2 (*n* = 25)5 (*n* = 9)1 (n = 2)1 (n = 2)0 (n = 1)1 (n = 1)26 (*n* = 113)Positive family history14 (*n* = 56)9 (*n* = 20)12 (*n* = 24)2 (n = 9)0 (*n* = 3)1 (n = 1)0 (n = 1)0 (n = 1)38 (*n* = 115)Age group Neonatal4413110220072 Infancy6340000013  \> Infancy (\>  1 year)114119101138Clinical presentation Neonatal or intermittent encephalopathy, or seizures5117190310192 Liver disease (deranged liver enzymes)6520000013 Failure to thrive311100017 Developmental delay6579000027 Other neuropsychiatric/ behavioural/ ataxia/ spasticity symptomsNil046101012 Mutations performed55162253211105 Results obtained55151853211100Outcome Death4412110120070 Alive105148101140 Development: Delayed7578100028 Development: Normal or near normal2170001112 Diet -Protein restriction+ medications65108100131 Lost to follow up/ not known7311100013*ASS1-D* Argininosuccinate synthetase type 1 deficiency, *ASL-D* Argininosucccinate lyase deficiency, *OTC-D* Ornithine transcarbamylase deficiency, *ARG-D* Arginase deficiency, *CPS1-D* CPS1 deficiency, *NAGS-D* N-acetyl glutamate synthase deficiency, *Citrin-D* Citrin deficiency, *LPI* Lysinuric protein intolerance

Clinical details were available for all 123 patients. Full clinical, laboratory, and outcome details are available in Additional file [1](#MOESM1){ref-type="media"}. Approximately three-fifth of patients (72/123, 58%) presented in the first 30 days of life (neonatal period), 88% of whom presented on or before day 7 of life (classical presentation). Thirteen cases presented in infancy between 1 and 12 months of life, and 38 after the first year of life. Overall male to female ratio was 1.7:1 (2.25:1 in OTC deficiency, 1.65:1 in non-OTC deficiency). Consanguinity and a positive family history were noted in 23% (26/113) and 33% (38/115) of families, respectively. All families were unrelated except one where a non-consanguineous couple visited our clinic after losing their daughter on day 6 of life with encephalopathy and no other investigations. Husband's niece was detected to have citrullinemia type 1. Based on the history, the couple was tested and detected to be carriers of citrullinemia type 1. Apart from this, there were no related families.

Detailed description of all cases including demography, clinical presentations, family history, biochemical investigations, outcomes and prenatal diagnosis data (for subsequent pregnancies in parents of probands) are shown in Additional file [1](#MOESM1){ref-type="media"}: Table S1. A large number of cases presented with encephalopathy with or without seizures (94/123, 76%), either in neonatal period or later (Table [1](#Tab1){ref-type="table"}). Half of the patients in the late onset group presented with developmental delay (22/51, 43%). A significant number of children had features of liver disease (10.5%) and failure to thrive (3%) (Table [1](#Tab1){ref-type="table"}).

Outcome analysis {#Sec6}
----------------

Outcome data was available from 110 cases. Of these, 70 died and 12 patients are healthy and developing normally. The remaining 28 patients are surviving with varying degree of disability (Fig. [1](#Fig1){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}).Fig. 1Flowchart showing outcomes of UCD patients

Citrullinemia type 1 was the most frequently observed UCD and showed the worst outcome. Of 55 patients for whom outcome was known, 44 died (81.5%), 7 children survived with disability ranging from minor learning difficulties to severe global delay and seizures, and 3 children survived without disability: 2 of whom received liver transplantation, and 1 patient with a milder presentation of neonatal cholestasis and liver dysfunction that resolved over time. All except 2 deaths occurred in the first episode of illness in neonatal period. In the two children who survived the initial insult in neonatal period, there was severe failure to thrive, and death because of relentless progression of disease with intercurrent illnesses.

Outcomes in ASL and OTC deficiency cases were also poor with a total mortality of 50% (23/46 cases). In ASL deficiency survivors, all except 1 had some degree of disability. In OTC deficiency survivors, 5 of 8 girls and 2 of 6 boys have developmental delay and 3 girls and 4 boys were healthy (Table [1](#Tab1){ref-type="table"}, Additional file [1](#MOESM1){ref-type="media"}: Table S1). All the children who are doing well presented with mild symptoms of episodic vomiting.

Molecular genetic studies {#Sec7}
-------------------------

Molecular studies could be performed in 105 patients/families. All tests were targeted sequencing of genes based on preliminary biochemical diagnosis. Pathogenic or likely pathogenic variants were noted in 100 cases. Molecular analysis for specific genes did not reveal any pathogenic variant in 5 cases. Details of mutations are listed in Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}. Table [5](#Tab5){ref-type="table"} provides details of clinical presentation, and gene studies performed in mutation negative patients.Table 2Details of mutations in all patientsGeneMutationNumber of casesNo. of allelesReferenceExAC data base (allele frequency)PositionDNAProtein/ mRNATypeHomo zygousHetero/ Hemi zygousASS1Exon 5c.190G \> Ap.Val64IleMissense113Novel0.00003303Exon 5c.269G \> Ap.Gly90AspMissense102NovelNAExon 5c.271A \> Cp.Thr91ProMissense102Novel0.00003324Exon 5c.299G \> Ap.Arg100HisMissense011\[[@CR30]\]0.0001597Exon 5c.349G \> Tp.Gly117CysMissense102\[[@CR30]\]NAExon 5c.350G \> Ap.Gly117AspMissense011\[[@CR36]\]NAExon 6c.370G \> Ap.Asp124AsnMissense113\[[@CR37]\]NAExon 7c.470G \> Ap.Arg157HisMissense12125\[[@CR38]\]0.00009932Exon 9c.570T \> Ap.Tyr190TerPTC\*\*011NovelNAExon 12c.793C \> Tp.Arg265CysMissense317\[[@CR39]\]0.000008262Exon 12c.815G \> Ap.Arg272HisMissense204\[[@CR40]\]NAExon 13c.910C \> Tp.Arg304TrpMissense204\[[@CR38]\]0.00004119Exon 14c.970G \> Ap.Gly324SerMissense102\[[@CR38]\]0.00004952Exon 14c.1088G \> Ap.Arg363GlnMissense011\[[@CR30]\]0.000008792Exon 15c.1139delAp.Glu380Argfs\*20Deletion sbp\*215NovelNAExon 15c.1168G \> Cp.Gly390ArgMissense23147\[[@CR38]\]NATotal5010110ASLExon 3c.89_94delinsGTCGTAp.Tyr30_Asp31delinsCysArgDEL INS\*\*\*011NovelNAExon 5c.326C \> Gp.Thr109ArgMissense011NovelNAExon 5c.337C \> Tp.Arg113TrpMissense102\[[@CR16]\]0.00006783Exon 7c.509G \> Ap.Ser170AsnMissense022\[[@CR41]\]NAExon 8c.593C \> Tp.Pro198LeuMissense102NovelNAExon 9c.637C \> Tp.Arg213TerPTC033\[[@CR42]\]0.000008417Exon 9c.649C \> Tp.Arg217TerPTC102Novel0.000008443Exon 11c.733T \> Cp.Trp245ArgMissense011NovelNAExon 11c.749T \> Ap.Met250LysMissense011Novel0.00000854Exon 12c.857A \> Gp.Gln286ArgMissense215\[[@CR43]\]0.00007499Exon 12c.913G \> Ap.Gly305ArgMissense011NovelNAExon 12c.967A \> Gp.Lys323GluMissense102NovelNAExon 12c.978G \> Cp.Gln326HisMissense011\[[@CR41]\]0.00003771Exon 16c.1153C \> Tp.Arg385CysMissense102\[[@CR44]\]0.00006732Exon 17c.1297A \> Cp.Ser433ArgMissense022\[[@CR41]\]NAExon 17c.1300G \> Tp.Val434LeuMissense022\[[@CR41]\]0.000008284Total71630OTCExon 1c.274C \> Tp.Arg92TerPTC011\[[@CR45]\]NAExon 1c.275G \> Ap.Arg92GlnMissense011\[[@CR45]\]NAExon 4c.386G \> Ap.Arg129HisMissense033\[[@CR32]\]NAExon 5c.421C \> Tp.Arg141TerPTC011\[[@CR33]\]NAExon 5c.535C \> Tp.Leu179PheMissense011\[[@CR46]\]NAExon 6c.604C \> Tp.His202TyrMissense011\[[@CR47]\]NAExon 7c.674C \> Tp.Pro225LeuMissense022\[[@CR48]\]NAExon 7--8c.773_790delp.Asn258_263delDeletion 18 bp011NovelNAExon 8c.805G \> Ap.Gly269ArgMissense011NovelNAExon 8c.829C \> Tp.Arg277TrpMissense011\[[@CR49]\]NAExon 8c.835C \> Tp.Gln279TerPTC011\[[@CR50]\]NAExon1--10Whole gene deletionLarge deletion044\[[@CR51]\]NATotal01818ARG1Exon 1c.2 T \> Cp.Met1?Initiation codon102NovelNAExon 3c.132_146delp.Gln44_Lys48delDeletion 15 bp011NovelNAExon 3c.295G \> Ap.Gly99ArgMissense011Novel0.00001658Exon 5c.551delCp.Pro184Leufs\*7PTC102NovelNAIntron 7c.802 + 2 T \> GSplice siteSplice site102NovelNAExon 8c.877delGp.Val293TerPTC102NovelNATotal4210CPS1Intron 3c.236 + 4A \> G (NM_001875.4)Splice siteSplice site102NovelExon 19c.2339G \> Ap.Arg780HisMissense102\[[@CR52]\]0.00003304Exon 21c.2623A \> Gp.Lys875GluMissense102\[[@CR18]\]0.002427NAGSExon 3c.787G \> Tp.Glu263TerPTC102NovelNAExon 4c.991C \> Tp.Gln331TerPTC102NovelNASLC25A13Exon 7c.650delTp.Phe217Serfs\*33Deletion sbp011\[[@CR11]\]Exon 9c.869T \> Cp.Ile290ThrMissense011\[[@CR11]\]0.000008256SLC7A7Exon 15c.158C \> Tp.Ser53LeuMissense102\[[@CR12]\]NAGRAND TOTAL6748100\*sbp single base pair, \*\**PTC* Premature termination codon, \*\*\**DEL INS* Deletion insertionTable 3Evaluation of pathogenicity of novel variants using in-silico prediction toolsGeneMutationProtein changeMutation tasterLRTSIFTPROVEANDANNExACdbSNPASS1c.190G \> Ap.Val64IleDisease causingNeutralToleratedNeutral0.97910.00003303556,297,791c.269G \> Ap.Gly90AspDisease causingUnknownDamagingDamaging0.9985Not Present1,422,867,920c.271A \> Cp.Thr91ProDisease causingUnknownDamagingDamaging0.99630.00003324769,018,733c.570C \> Ap.Tyr190TerDisease causingUnknownNANA0.9957Not PresentNot Presentc.1139delAp.Gln380Argfs\*20Disease causingNANANANANot Present1,213,378,896ASLc.89_94delinsGTCGTAp.Tyr30_Asp31delinsCysArgDisease causingNANANANANot presentNot presentc.326C \> Gp.Thr109ArgDisease causingDeleteriousDamagingDamaging0.9938Not presentNot Presentc.593C \> Tp.Pro198LeuDisease causingDeleteriousDamagingDamaging0.9992Not Present1,282,829,485c.649C \> Tp.Arg217TerDisease causingNeutralNANA0.99720.000008443369,879,957c.733T \> Cp.Trp245ArgDisease causingDeleteriousDamagingDamaging0.9941Not presentNot Presentc.749T \> Ap.Met250LysDisease causingDeleteriousDamagingDamaging0.9791Not present754,634,171c.913G \> Ap.Gly305ArgDisease causingDeleteriousDamagingDamaging0.9993Not presentNot Presentc.967A \> Gp.Lys323GluDisease causingDeleteriousDamagingDamaging0.9987Not presentNot PresentOTCc.773_790delp.Asn258_263DelDisease causingNANANANANot presentNot Presentc.805G \> Ap.Gly269ArgDisease causingDeleteriousDamagingDamaging0.9992Not PresentNot PresentARG1c.2T \> Cp.Met1ThrDisease causingDeleteriousDamagingNeutral0.9809Not PresentNot Presentc.132_146delp.Gln44_Lys48delDisease causingNANANANANot PresentNot Presentc.295G \> Ap.Gly99ArgDisease causingDeleteriousDamagingDamaging0.99930.00001658753,829,097c.551delCp.Pro184Leufs\*7Disease causingNANANANANot PresentNot Presentc.802 + 2 T \> GSplice siteDisease causingNANANA0.9948Not PresentNot Presentc.877delGp.Val293TerDisease causingNANANANANot PresentNot PresentCPS1c.254 + 4A \> GSplice siteDisease causingNANANA0.9747Not PresentNot PresentNAGSc.787G \> Tp.Glu263TerDisease causingDeleteriousNANA0.9963Not PresentNot Presentc.991C \> Tp.Gln331TerDisease causingDeleteriousNANA0.9973Not Present1,445,639,047Mutation Taster: An in silico prediction tool for the pathogenicity of a variant based on evolutionary conservation, splice-site, mRNA, protein and regulatory features. The potential is predicted by a naive Bayes classifierLRT: Likelihood ratio test (LRT) predicts deleterious variants through identification of highly conserved amino acid regions using a comparative genomics data set of 32 vertebrate species. Range 0 to 1SIFT: SIFT (sorts intolerant from tolerant) is an in silico prediction tool for nonsynonymous variants based on sequence homology derived from closely related sequences collected through PSI-BLAST. Range 0 to 1 with values less than 0.05 usually considered intolerant. 40% of the values in this database are below 0.01PROVEAN: Protein Variation Effect Analyzer is an in silico tool that predicts how nonsynonymous, MNP, or in-frame indel variant will affect a protein's biological function. The prediction is based on alignment-based scores derived from pairwise sequence alignments between the query sequence and each of the related sequences at the protein level. Range − 14 to + 14DANN: DANN is a pathogenicity scoring methodology developed by Daniel Quang, Yifei Chen and Xiaohui Xie at the University of California, Irvine. It is based on deep neural networks. The value range is 0 to 1, with 1 given to the variants predicted to be the most damagingTable 4Types of mutations detectedTotal number of patients with mutations100Number of patients with homozygous mutations67Total number of mutations58Total number of novel mutations24Missense mutations39Premature termination codon10Initiation codon mutation1Splice site mutation2Small insertions/ deletions5Large deletion1Table 5Patients in whom molecular studies showed no mutationsGene studiedS.No (as in Additional file [1](#MOESM1){ref-type="media"})Age at presentationSex (proband)ConsanguinityFamily history of similar diseaseClinical features in probandAmino acids levels by MS/MS on dried blood spot (μmol/l)GC-MS in urineAmmonia level (in μmol/l)ASL784 daysMaleNoNoNeonatal encephalopathy, convulsions, lethargy, reduced feedingCitrulline- 2557, ASA- 753.19Increased orotate 393NKOTC864 daysMaleNoYes, previous 2Neonatal encephalopathy and deathsNKAllopurinol challenge test in mother - increase in orotateNK935 daysMaleNoYesNeonatal encephalopathy and deathNKIncreased orotateHigh962 yearsFemaleNoYes, elder sisterEncephalopathy, Febrile illness with high ammoniaNormal amino acid levels Citrulline 15, arginine 15, ornithine 146Increased orotateHigh 1600981.5 yearsFemaleNoNoEncephalopathy, Vomiting, awkward behaviour, high ammoniaNKIncreased orotateLevel NK

A total of 58 different mutations were detected in 100 patients, 16 of which were observed in *ASS1* gene and *ASL* gene each, 12 mutations in *OTC* gene, and 6 mutations each in *ARG1* gene, 3 in *CPS1,* 2 in *NAGS* and *SLC25A13* genes, and one in *SLC7A7* gene (Table [2](#Tab2){ref-type="table"}). Twenty four mutations were novel. Of 100 patients in whom the diagnosis was genetically confirmed, 67 were homozygous and 15 were compound heterozygous, 12 were hemizygous and 6 were heterozygous (for an *OTC* mutation).

*ASS1* gene sequencing was performed in 55 out of 61 cases. The two most common mutations, c.470G \> A (p.Arg157His) and c.1168G \> A (p.Gly390Arg) were observed in 72 alleles out of a total of 110 alleles (65.5%). The missense mutation, c.1168G \> A occurred twice more frequently (47/110 alleles \[42.7%\]) than c.470G \> A (25/110 alleles \[22.7%\]). Five mutations were novel (Table [3](#Tab3){ref-type="table"}).

Sequencing of *ASL* gene revealed more varied findings with 16 mutations in 15 cases. Interestingly, all mutations were in compound heterozygous states in the 8 cases from Centre 1 whereas all mutations were noted in homozygous form in the patients from Centre 2. Four mutations were noted to be recurrent: c.509G \> A (p.Ser170Asn), c.637C \> T (p.Arg213Ter), c.1297A \> C (p.Ser433Arg) and c.1300G \> T (p.Val434Leu), occurring in 2, 3, 2 and 2 alleles, respectively. Eight mutations were noted to be novel.

*OTC* gene sequencing was performed in 22 of 26 cases. No mutation was identified in 4 cases (one male, 2 female probands and 1 carrier mother) after full sequencing of *OTC* gene as well as MLPA analysis for deletions/duplications. The most common mutation noted was a whole gene deletion in 4 cases, accounting for 22.2% (4/18) cases. Rest of mutations were single nucleotide substitutions, missense or nonsense mutations. Pathogenic variants were also identified in arginase deficiency (5 cases), CPS1 deficiency (3 cases), two cases of NAGS deficiency, one case each citrin deficiency \[[@CR10]\] and LPI \[[@CR11]\]. All pathogenic variants in *ARG1* and *NAGS* genes were novel (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}). Another novel pathogenic variant was noted in *CPS1* gene. The pathogenicity of this variant, c.236 + 4A \> G (NM_001875.4) was checked via RNA studies at Zurich. On RNA level, as a consequence of this splice-site mutation, two alternatively spliced transcript variants were observed: the majority of transcripts showed complete skipping of exon 2 (r.127_236del, p.Ala43Valfs\*7) but also partial skipping of exon 2 (r.206_236del, p.Glu70Thrfs\*70) was observed. Both parents are carriers of the mutation, confirming obligate heterozygosity.

Prenatal diagnosis {#Sec8}
------------------

Mutation analysis led to successful prenatal diagnoses in 30 pregnancies in 25 families (Table [6](#Tab6){ref-type="table"}). This included one couple that opted for pre-implantation genetic diagnosis (PGD) after having an affected fetus in a preceding pregnancy. In this case the result was normal, and the couple delivered a healthy baby. Of the 29 prenatal analyses, 11 pregnancies were found to carry fetuses with no mutation (normal), 13 with carrier fetuses (including 2 OTC female carriers, both of whom are doing well after birth) and 5 carried affected fetuses. Amongst 19 pregnancies in families with ASS or ASL deficiency, 4 pregnancies were found to have fetuses affected with disease (21%).Table 6Prenatal diagnosis in families with UCDsS. No (as per Additional file [1](#MOESM1){ref-type="media"})Diagnosis in probandAge at presentation in probandsConsanguinity among parentsMutations in probandProtein changeNumber of PNDResults of PND5ASS1-D6 daysNoc.1168G \> Ap.Gly390ArgOnceNot affected (carrier)7ASS1-D5 daysYesc.470G \> Ap.Arg157HisTwiceOne affected, one unaffected (carrier)10ASS1-D5 daysNoc.1168G \> Ap.Gly390ArgOnceNot affected16ASS1-D7 daysNoc.570T \> A c.350G \> Ap.Tyr190Ter & p.Gly117AspOnceAffected17ASS1-D4 daysNoc.1139delAp.Glu380Arg fs\*20OnceNot affected (carrier)18ASS1-D4 daysNoc.470G \> Ap.Arg157HisOnce, one PGDAffected, PGD pregnancy healthy baby19ASS1-D6 daysYesc.970G \> Ap.Gly324SerOnceNot affected (carrier)22ASS1-D2 daysYesc.470G \> Ap.Arg157HisOnceNot affected (carrier)27ASS1-D4 daysNoc.1168G \> Ap.Gly390ArgOnceNot affected30ASS1-D5 daysNoc.470G \> Ap.Arg157HisOnceNot affected (carrier)33ASS1-D3 daysNoc.1168G \> Ap.Gly390ArgOnceNot affected35ASS1-DNeonatalNoc.1168G \> Ap.Gly390ArgOnceNot affected61ASS1-DNeonatalNoc.1168G \> Ap.Gly390ArgOnceNot affected (carrier)62ASL-D4 daysNoc.509G \> A c.1297A \> Cp.Ser170Asn p.Ser433ArgTwiceAffected once, not affected second time65ASL-D5 daysNoc.637C \> T c.1300G \> Tp.Arg213Ter p.Val434LeuOnceNot affected (carrier)70ASL-D9 daysYesc.913G \> A c.749 T \> Ap.Gly305Arg p.Met250LysOnceNot affected (carrier)87OTC-D6 daysNoc.674C \> Tp.Pro225LeuTwiceNot affected (once carrier, once no mutation)91OTC-D3 daysYeswhole gene deletion (mother tested)OnceCarrier female92OTC-D3 daysNoc.274C \> Tp.Arg92TerOnceNot affected94OTC-D5 daysYesc.421C \> Tp.Arg141TerTwiceFirst affected male, second carrier female97OTC-D2 daysNowhole gene deletion (mother tested)OnceNot affected101OTC-D5 yearsNowhole gene deletion (mother tested)OnceNot affected119CPS1 -DNKNKc.2623A \> Gp.Lys875GluOnceNot affected120NAGS-DNKNKc.991C \> Tp.Gln331TerOnceNot affected121NAGS-DNeonatalYesc.787G \> Tp.Glu263TerOnceNot affected (Carrier)NK: Not known, PGD: Pre-implantation genetic diagnosis

Discussion {#Sec9}
==========

Urea cycle disorders occur universally with varying frequencies in different populations \[[@CR1], [@CR21]--[@CR23]\]. While OTC deficiency has been reported to be the most commonly occurring UCD, citrullinemia type 1 is reported to be less common \[[@CR3], [@CR5], [@CR24]\]. In contrast, in our cohort, citrullinemia type 1 contributed to about half (61/123, 49.6%), thus making citrullinemia type 1 the most commonly occurring UCD in this cohort. The data was pooled from two centres, both showing similar results independently. OTC deficiency was observed with lower frequency in the cohort. In fact, the total incidence for OTC deficiency was less than half of that found for citrullinemia type 1. Although suspected in few additional patients (hyperammonemia with high urinary orotic acid expected in OTC deficiency), there was insufficient evidence to prove OTC deficiency in some patients because of the difficulty in performing enzyme based diagnosis (which would have required a liver biopsy) or due to lack of mutations in the *OTC* gene despite full gene study (sequencing as well as testing for larger deletions and duplications by MLPA). These difficulties are however well known and described earlier in large studies \[[@CR25]\]. Many factors contributed to the failure to achieve a definitive diagnosis in all patients: the lack of availability of enzyme diagnostics at any centre in India, the invasiveness of the test (liver biopsy) along with difficulty in shipment of liver biopsy specimens in frozen state to another centre abroad, and the overall cost involved. It is therefore likely that cases of OTC deficiency are being missed in India, as known from literature \[[@CR25]\].

The situation is different in the case of citrullinemia type 1, where a very high citrulline level on dried blood spot MS/MS can be reliably detected leading to further gene studies confirming the diagnosis. Presence of ASA in blood or urine is indicative of ASL deficiency, and for elevated plasma arginine of arginase deficiency.

Urea cycle disorder commoner than OTC deficiency has also been noted in Saudi Arabian population, where ASL deficiency has been described as the most common UCD. Consanguinity in this particular population seems to be one leading explanation \[[@CR26]\]. Parallels can be drawn with the Indian population where both consanguinity and closed community marriages are the norm, leading to genetic isolates. This may be a part explanation to citrullinemia type 1 being more common in India. In our cohort, consanguinity was noted in 23% families. Consanguinity and close community marriages are important factors leading to increased occurrence of recessive disorders, at least in India \[[@CR27]\].

In our study, 10 couples (and 6 expectant mothers in case of OTC deficiency) were tested in absence of a sample from index patient, and their gene study detected heterozygous mutations, suggesting an accurate diagnosis in their probands. In seven couples, citrullinemia type 1 was suspected based on elevated plasma citrulline in index patient and these couples were only tested for mutations in *ASS1* gene.

The presentation in most Indian children was similar to what is known in literature, with both neonatal classic form and late onset presentations. In our cohort, the neonatal classic presentation was more common in all UCDs except arginase and citrin deficiency. This finding is somewhat different from other studies where majority of presentations are beyond first 30 days of life \[[@CR1], [@CR28], [@CR29]\]. The more common early presentation in our cohort may have been a bias because neonatal cases are recognized more easily in view of a careful medical supervision in the neonatal period. A recent study from Europe reported 50 patients of UCD detected both symptomatically (39/50) and NBS/presymptomatically (11/50). In this cohort, 28 of 39 symptomatically detected patients presented with neonatal encephalopathy, thus corroborating with our observation of a neonatal presentation being more common \[[@CR5]\]. The high mortality among the neonatal encephalopathy group in our cohort was similar to the cohort reported from Europe \[[@CR5]\].

A family history of previous sibling deaths was present in approximately 33% of families. This highlights the immense burden of the disease on the families, and the ignorance as well as lack of facilities denying these families of an opportunity for early diagnosis and prompt treatment. This would have prevented the suffering, either by successful treatment of the index child or by prenatal diagnosis. Molecular diagnosis thus helped the families in prevention of recurrence of this difficult group of disorders.

Molecular analysis revealed several interesting findings besides being immensely helpful in family counseling. For *ASS1* gene, there were two common mutations, p.Gly390Arg and p.Arg157His which constituted 65.5% of cases. These two are previously reported mutations and are present globally \[[@CR30]\]. Most common mutation seen in multiple ethnic group is p.Gly390Arg except in the east Asian population where another mutation, c.421-2A \> G is the commonest \[[@CR31]\]. Another mutation, p.Arg265Cys seen in our population was common to the Japanese population \[[@CR31]\]. There seemed to be a good genotype-phenotype correlation, which is in agreement with reported literature \[[@CR24]\]. Two recurring mutations, p.Arg213Ter and p.Ser170Asn, were found in *ASL* gene.

In a significant number of OTC deficiency patients, a whole gene deletion was detected. In this disorder, whole gene deletions as well as nonsense mutations were noted either in neonatally presenting severely affected males or in manifesting females, while missense mutations were noted in mildly affected boys. This finding is also in agreement with literature \[[@CR21], [@CR32], [@CR33]\]. The mutation p.Arg129His, showing a mild phenotype with excellent prognosis, has previously been described \[[@CR34]\]. Similarly, p.Arg277Trp is known to be a mild mutation, reported even in male transmission \[[@CR35]\].

Molecular analysis enabled successful prenatal diagnosis in 30 pregnancies with no false negative results. This is an effective way of reducing the disease-related morbidity and mortality, until appropriate facilities are made available for early diagnosis and treatment.

Conclusions {#Sec10}
===========

This is the first comprehensive report of mutations in UCDs from the Indian subcontinent. Increasing availability of gene sequencing has enabled higher numbers of prenatal diagnosis for UCDs. Establishing a precise molecular diagnosis by mutation analysis is helpful not only for accurate genetic counseling but also for accurate carrier testing, which is an efficient way for reducing the morbidity and mortality associated with the disease through prenatal diagnosis.

Additional file
===============

 {#Sec11}

Additional file 1:Details of clinical, biochemical and molecular analysis and of outcomes and prenatal diagnoses in each patient in the study. The data provides complete information about each patient enrolled in the study. This includes the demographic details, clinical and family history, the laboratory investigations (biochemical as well as mutation analysis), an outcome data and information about prenatal diagnosis in the particular family. Each patient is assigned a number, and all patients belong to different families, thus 123 patients from 123 families were enrolled. Data is pooled from two genetic centres differentiated by use of different color font in the table -- black for centre 1 and maroon for centre 2. (XLSX 30 kb)

ARG

:   Arginase

ASL

:   Argininosuccinate Lyase

ASS1

:   Argininosuccinate Synthetase 1

CPS1

:   Carbamoyl phosphate synthetase 1

GCMS

:   Gas chromatography mass spectrometry

HPLC

:   High performance liquid chromatography

ICU

:   Intensive Care Units

MS/MS

:   Mass spectrometry, mass spectrometry/ Tandem mass spectrometry

NAGS

:   N-acetyl glutamate synthase

OTC

:   Ornithine Transcarbamylase

UCD

:   Urea cycle disorders

The authors acknowledge the valuable contributions from all the collaborators and referring physicians for patients and/or samples. Mutation analysis at University Children's Hospital Zurich was supported by the Swiss National Science Foundation (grant 310030_153196 to JH). We duly acknowledge the support of all our patients and their families, and staff members, especially Mr. Kuldeep Singh, Dr. Divya Thomas, Dr. Sanjeev Pandey, Dr. Divya Agarwal, Dr. Moni Tuteja, Dr. Udhaya Kotecha, Dr. Pratima Dash, Dr. Sangeeta Khatter, Dr. Vinu N, Dr. Kanika Singh, Dr. Vibha Jain, Ms. Achint Kaur, Mr. Naresh Kashyap, Mr. Rajendra Mishra and others at the Institute of Medical Genetics & Genomics at SGRH. We also acknowledge the contribution by way of referring patients and samples from our collaborators all over India, especially Dr. Madhulika Kabra & Dr. Neerja Gupta (AIIMS, New Delhi), Dr. Seema Kapoor (MAMC, New Delhi), Dr. Sujatha Jagadeesh & Dr. Solomon F D Paul (Chennai), Dr. Meenakshi Bhat (Bangalore), Dr. Balakrishnan (Kerala), Dr. Amandeep Raj (Delhi), Dr. Shubha Phadke (SGPGI, Lucknow), Dr. Neelam Mohan (Gurgaon), Dr. Ashish Sahani & Dr. Rohit (Delhi), Dr. Rajeev Bansal and Dr. Vivek Jain (Jaipur), Dr. Saurabh Chopra (Delhi) and others without whose support the study wouldn't have been possible. We acknowledge the contribution of Dr. Namrata Singh and team from Turacoz Healthcare Solutions for editing the manuscript specifically for language and syntax.

Funding {#FPar1}
=======

Partial funding was availed from the Swiss National Science Foundation (grant 310030_153196 to JH).

Availability of data and materials {#FPar2}
==================================

The data collected was from two centres where patients were managed for the particular genetic disorder.

SBM and JH contributed to design of study and manuscript writing. SBM, RDP, ABJ, ICV were involved in clinical management of patients. JH, KK, SK, RS, DG, DM were involved in molecular testing of patients and their parents. JV, SY and YS contributed to biochemical analysis and prenatal diagnosis of patients. JH, SK, RS, DG and DM contributed to prenatal diagnosis of patients. ICV and JH contributed to critically analyzing the manuscript and providing important intellectual contents. All authors read and approved the final manuscript.

Ethics approval and consent to participate {#FPar3}
==========================================

Not applicable.

Consent for publication {#FPar4}
=======================

Consent has been taken from all the authors. No individual patient data including videos, voice recordings or images have been submitted for publication.

Competing interests {#FPar5}
===================

The authors declare that they have no competing interests.

Publisher's Note {#FPar6}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
